Equifax shares jump 5.51% intraday as valuation reassessment and analyst upgrades highlight undervaluation potential.

Equifax surged 5.51% intraday after reporting stronger-than-expected Q4 2025 results, with revenue rising 9% to $1.551 billion and earnings of $2.09 per share exceeding forecasts. The rebound followed a post-earnings sell-off that pushed the stock to a 52-week low, as investors reassessed its valuation and growth outlook. Management’s full-year 2026 guidance—projecting 10% revenue growth to $6.7 billion and adjusted EPS of $8.30–$8.70—reinforced optimism, while analyst upgrades and insider buying signaled confidence in Equifax’s AI and cloud initiatives. Despite scrutiny over its Medicaid verification practices and price hikes, the stock’s rally reflected renewed focus on its long-term earnings potential and operational momentum.